Neovacs to present at two major Investor Conferences:
August 30 2016 - 2:15AM
Neovacs (Alternext Paris:ALNEV), a leader in
active immunotherapy for the treatment of autoimmune diseases,
today announced CEO Miguel Sieler will present at the 18th Annual
Rodman & Renshaw Global Investment Conference and Bio
Europe 2016.
The Rodman & Renshaw Global Investment
Conference, being held September 11-13 in New York, NY, will host
over 265 public and private companies, and several thousand
attendees. The conference will bring together a vast audience of
financial and strategic investors with growth companies in the
fields of healthcare, natural resources, technology, media and
telecommunications, and cleantech. In addition to corporate
presentations, the conference facilitates one-on-one meetings with
members of the investment community.
Miguel Sieler, CEO of Neovacs, will present the
company at Rodman & Renshaw on Monday September 12, from 10:50
to 11:15 am ET at the New York Palace Hotel, on the fourth floor in
the Louis Room.
Neovacs will also present at Bio Europe, which will
take place November 7-9 in Cologne, Germany. This conference is one
of the world’s most important meetings for the biotech industry.
This year the Bio Europe event will draw over 3,500 attendees from
60 countries, representing 1,800 companies. It will provide Neovacs
with the opportunity to meet with a vast audience of financial and
strategic investors, as well as potential high-level partners.
About Neovacs
Created in 1993, Neovacs is today a leading
biotechnology company focused on an active immunotherapy technology
platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company’s proprietary
technology for inducing a polyclonal immune response (covered by
five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an
immunotherapy being developed for the indication of lupus and
dermatomyositis. Neovacs is also conducting preclinical development
works on other therapeutic vaccines in the fields of auto-immune
diseases, oncology and allergies. The goal of the Kinoid approach
is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.
www.neovacs.fr
Contacts
NEOVACS – Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 14
cmasson@neovacs.com
Investor Relations / Financial Communication Germany – MC Services
Raimund Gabriel
+49-89-21-02-28-30
raimund.gabriel@mc-services.eu
Press / U.S. Inquiries – The Ruth Group
Lee Roth / Joseph Green
+1-646-536-7012 / 7013
lroth@theruthgroup.com / jgreen@theruthgroup.com
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovacs (EU:ALNEV)
Historical Stock Chart
From Jul 2023 to Jul 2024